Regional Collaboration Sample Clauses

Regional Collaboration. 5.7.12.1. There is a statutory requirement for regional collaboration to be undertaken and close working relationships have already been formed with the adjoining neighbouring authorities, with key group meetings already established.
Sample 1Sample 2
AutoNDA by SimpleDocs
Regional Collaboration. EFC Partnership solutions should be sought through regional collaboration whenever feasible. Guiding Principles As Denver and Xcel Energy, in conjunction with the community, seek to achieve our shared goals, we will follow certain tenets. These principles will supply the “how” of implementing our shared vision and executing the EFC Partnership.
Sample 1
Regional Collaboration. Within the context of the NHS Highland IA, plans are in development for an Elective Care Centre, close to Raigmore Hospital, which will bring additional operative capacity into the NoS for Cataracts, Hips and Knees. Planning is being progressed with NHS Highland in anticipation of optimal patient pathways across the North to support patients to have access to these new facilities. Work to determine the detail of these pathway developments is ongoing on collaborative basis, and there are regional working groups exploring regional sustainability and access issues for Orthopaedics and Ophthalmology. This increase in capacity in NoS for these key specialties clearly provides opportunity, with pathways and resource implications to be determined. In addition, cross-board links with NHS Highland and NHS Tayside are developing in relation to many (sub) specialties including: Upper GI Cancer Surgery, Radiology, Dermatology, Cardiology workstreams and the developing region approach to Laboratory Services.
Sample 1
Regional Collaboration. Where consistent with the goal of achieving a sufficient water supply, the 19 City should act to maximize regional collaboration, synergies or collateral benefits, including, but 20 not limited to, assisting neighboring communities to address their water supply issues, reversing or 21 slowing seawater intrusion and habitat and fishery restoration. 22
Sample 1

Related to Regional Collaboration

  • AREAS OF COLLABORATION The School will collaborate under Xxxx Innovation Mission to establish, operate and support ATL in India within the school premises with financial support from NITI Aayog.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development cooperation 1. The Parties recognise that development cooperation is a crucial element of their Partnership and an essential factor in the realisation of the objectives of this Agreement as laid down in Article 1. This cooperation can take financial and non-financial forms.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • PRINCIPLES OF COLLABORATION The parties agree to adopt the following principles when carrying out the Project (Principles):

Time is Money Join Law Insider Premium to draft better contracts faster.